Latest Headlines

31. Antios Therapeutics Announces Agreement With IRBM, INGM And OSR To Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs) 11/15/2021

    Antios Therapeutics, Inc. ("Antios"), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), and IRBM, a drug discovery and early development research institute and global contract research organization, announced today they entered into an agreement for Antios to purchase the IP rights to a novel series of fourth-generation capsid assembly modulators (CAMs) being developed for the treatment of HBV.

32. UBC Researchers Train Computers To Predict The Next Designer Drugs 11/15/2021

    UBC researchers have trained computers to predict the next designer drugs before they are even on the market, technology that could save lives.

33. Novartis Licenses Patented Drug-Discovery Platform Technologies From Housey Pharma 11/11/2021

    Housey Pharma (http://www.housey.com) has entered into a license agreement of its core-enabling technologies for new-drug discovery with Novartis Institutes for BioMedical Research, Inc., (“Novartis”). The announcement was made today by Gerard Housey, M.D., Ph.D., founder and CEO of Housey Pharma, based in Southfield, Mich.

34. Abveris Announces Multi-Target, Multi-Year Therapeutic Antibody Discovery Collaboration With Prometheus Biosciences 11/11/2021

    Abveris, a leader in antibody drug discovery, today announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris's role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases.

35. ICON Announces The Expansion Of Its Accellacare Site Network 11/10/2021

    ICON plc, a global provider of drug development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, today announced that its Accellacare Site Network has expanded in reach and capabilities through new partnerships with six research sites across four countries.

36. MEI Pharma And Kyowa Kirin Receive Orphan Drug Designation For Zandelisib For The Treatment Of Follicular Lymphoma 11/10/2021

    MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin), a global specialty pharmaceutical company that utilizes the latest biotechnology to discover and deliver novel medicines, today announced that the U.S. Food and Drug Administration (FDA) granted orphan-drug designation (ODD) to zandelisib for the treatment of follicular lymphoma.

37. Repurposed Cancer Treatments Could Be Potential Alzheimer’s Drugs 11/10/2021

    Existing and emerging cancer drugs could be repurposed as therapies to be tested in clinical trials for people at genetic risk of Alzheimer’s disease, according to a new study published in Science Advances. Research combining analysis of brain protein alterations in these individuals as well as laboratory experiments in animal models and cell cultures could help scientists identify existing drugs to test for their potential as Alzheimer’s interventions more quickly.

38. New Drug Offers Hope For Pancreatic Cancer Patients 11/10/2021

    All the money in the world couldn’t save Apple co-founder Steve Jobs from pancreatic cancer, but a world first drug developed by UniSA scientists may provide the breakthrough for 500,000 other people currently battling the disease.

39. Cellaria Inc. Launches New Portfolio Of Products For Modeling The Tumor Microenvironment And Patient-Specific Preclinical Drug Screening 11/9/2021

    Cellaria Inc (Wakefield, MA, USA), a scientific innovator with breakthrough tools for cancer research, has announced the availability of a series of new products, including a panel of cell culture media optimized to grow clinically relevant cell types, an extra-cellular fully defined neutral collagen matrix (ECM), and validated protocols for a scalable and reproducible testing of small patient cohorts for screening of novel drug compounds.

40. FDA Clears Pharmaxis Cancer Drug To Progress To Phase 2 Study In Liver Cancer 11/9/2021

    Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced that an Investigational New Drug application (IND) for a trial of PXS-5505 in hepatocellular carcinoma (HCC) patients has been cleared by the United States Food and Drug Administration (FDA).